Top Markets
Coin of the day
RVL Pharmaceuticals plc RVL Pharmaceuticals plc

RVL Pharmaceuticals plc

OSMT
Rang in Aktien #25637
Osmotica Pharmaceuticals plc, headquartered in Bridgewater, New Jersey,... Osmotica Pharmaceuticals plc, headquartered in Bridgewater, New Jersey, operates as a fully integrated biopharmaceutical company. The firm's primary focus involves the development and commercialization of various pharmaceutical products, serving markets in the United States, Argentina, and Hungary. Their actively promoted product lineup includes M-72, an extended-release methylphenidate hydrochloride tablet designed to treat attention deficit hyperactivity disorder (ADHD), and Osmolex ER, an extended-release amantadine formulation used for Parkinson's disease and specific drug-induced movement disorders in adults. They also offer Upneeq, an oxymetazoline hydrochloride ophthalmic solution prescribed for blepharoptosis (drooping eyelids). In their development pipeline, Arbaclofen extended-release tablets are currently undergoing Phase III clinical trials for managing spasticity associated with multiple sclerosis, while OS870 is in Phase I trials for neurodegenerative disorders. Beyond these, Osmotica provides women's health solutions, such as Divigel for menopause management and OB Complete, a dietary supplement tailored for the prenatal, pregnancy, and postnatal periods. The company's broader portfolio also encompasses numerous non-promoted pharmaceutical products. These include methylphenidate ER tablets for ADHD, venlafaxine ER tablets addressing major depressive and social anxiety disorders, hydromorphone ER for pain relief, and nifedipine ER for hypertension. Other offerings feature sodium benzoate/sodium phenylacetate for hyperammonemia, oxybutynin ER for overactive bladder, and prescription prenatal vitamins. Additionally, their non-promoted items comprise Lorzone, an immediate-release chlorzoxazone for acute musculoskeletal pain (when combined with rest and physical therapy), ConZip (tramadol hydrochloride) for pain management, and nitrofurantoin for urinary tract infections, alongside Osmodex and various other abbreviated new drug applications.
Aktienkurs
$1.11
Zuletzt synchronisiert: 2022-01-18
Marktkapitalisierung
$47.57M
Veränderung (1 Tag)
-1.77%
Veränderung (1 Jahr)
0.00%
Land
US
Handel RVL Pharmaceuticals plc (OSMT)

Kategorie

Operative Marge für RVL Pharmaceuticals plc (OSMT)
Operative Marge zum 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von RVL Pharmaceuticals plc beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2026 lag die operative Marge bei 0.00%.
Historie der operativen Marge von RVL Pharmaceuticals plc von 2026 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
Nicht genügend Daten für die angegebenen Daten.
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
38.59% -
US
28.81% -
NL
25.72% -
AU
0.00% -
CH
-149.01% -
US
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.